Stoke Therapeutics assumed with an Outperform at Leerink

Leerink analyst Marc Goodman assumed coverage of Stoke Therapeutics with an Outperform rating and $18 price target The firm said there is “significant” unmet need for the treatment of Dravet syndrome, as all current products are symptom-based that focused on seizure reductions with limited efficacy. Leerink believes a disease-modifying therapy like STK-001 will be welcomed by physicians and patients, and it would become a blockbuster as the first-in-class product.